12 stories found
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen The Wall Street Journal
Novo Nordisk's shares experienced a significant drop after its new obesity drug failed to outperform Eli Lilly's Zepbound in clinical trials.
Eli Lilly has introduced a new, more convenient form of its obesity drug Zepbound, offering a month's worth of doses in a single pen to encourage wider usage.
Novo has been downgraded by J.P. Morgan, as its next-generation obesity drug is reportedly trailing behind Lilly’s Zepbound in market performance.
Novo Nordisk's shares dropped significantly after its new obesity drug did not demonstrate superior efficacy compared to Zepbound.
Novo Nordisk's shares experienced a significant drop after its obesity drug did not demonstrate superior efficacy compared to Zepbound in clinical trials.
Eli Lilly has announced a landmark trial demonstrating a major breakthrough with its Taltz-Zepbound drug combination for treating both psoriasis and obesity.
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs Reuters
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound WSJ
Novo Nordisk's shares experienced a significant drop after its obesity drug did not demonstrate superior efficacy compared to Zepbound in clinical trials.
Lilly announced that a regimen including its drug Zepbound demonstrated success in a clinical trial for treating psoriasis.